Constructive Bio’s 2025 achievements in non-canonical amino acid (ncAA) incorporation include expanded platform capabilities, new partnerships, and recognition from Nature…
Constructive Bio and RxCelerate have partnered to combine programmable biology and ncAA-enabled protein engineering with drug design and development capabilities,…
Constructive Bio was selected by Nature Biotechnology as a 2025 Editor’s Pick, recognising the company’s synthetic genomics platform and use…
Constructive Bio entered a collaboration with the Ellison Institute of Technology’s Generative Biology Institute (GBI) in Oxford, combining synthetic genome…
The New York Times covered the creation of Syn57, an E. coli strain with a 57-codon synthetic genome — the…
Constructive Bio has secured an exclusive licence for tRNA display technology, enabling directed integration of non-canonical amino acids (ncAAs) and…
Constructive Bio was named Best Performing R&D Platform Development Company of the Year at the One Nucleus Awards, recognising the…
Constructive Bio secured $58 million in Series A financing, bringing total funding to $75 million, to scale its BioForge fermentation…
Engineering the future of biology with revolutionary genome synthesis and expanded genetic code technology.
QUICK LINKS
JOIN OUR NEWSLETTER
© 2026 Constructive Bio. All rights reserved.